Physician

Imad Salah Modawi, M.D.

According to 2025 Medicare claims, Imad Modawi, M.D. (NPI: 1124224415) practices nephrology in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is KIDNEY DISEASE & HYPERTENSION, P.C. (NPI: 1982701256; TIN: 205396865) and primary practice location at 48503-5902. Modawi is affiliated with the McLaren High Performance Network, LLC (ACO ID: A3317), Mosaic ACO (ACO ID: A5033), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Modawi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 461 traditional Medicare patients, billed 1,857 HCPCS/CPT codes, and received $207,348 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,208 prescription claims across 342 beneficiaries totaling $432,823 in drug costs, led by Jardiance (Empagliflozin). 2023 DME data shows 13 claims. Open Payments data shows 8 records totaling $172. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $320,223 to $207,348. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $182,652 and ending at $432,823. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	622	3,791	$320,223
2016	675	3,789	$329,879
2017	701	3,800	$324,473
2018	556	2,742	$250,531
2019	519	2,270	$210,260
2020	468	2,297	$236,324
2021	448	2,041	$231,595
2022	440	2,051	$222,095
2023	389	1,535	$175,563
2024	461	1,857	$207,348

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	223	1,224	$182,652
2016	234	1,477	$241,553
2017	287	1,839	$275,996
2018	268	1,868	$180,576
2019	247	1,789	$112,764
2020	230	1,913	$193,630
2021	244	1,684	$171,095
2022	284	1,802	$217,191
2023	293	2,143	$409,223
2024	342	2,208	$432,823

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	13	$2,599
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	29	60	$263
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	176	204	$140
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	34	34	$123
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	253	1,125	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	151	301	$91

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	70	3,720	$70,082
Farxiga	Dapagliflozin Propanediol	72	3,240	$58,646
Lokelma	Sodium Zirconium Cyclosilicate	35	1,320	$32,214
Veltassa	Patiromer Calcium Sorbitex	20	1,016	$26,153
Trulicity	Dulaglutide	14	392	$12,868

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$172	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Imad Salah Modawi, M.D.?

Tedicare shows public-source Medicare data for Imad Salah Modawi, M.D. (NPI 1124224415), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Imad Salah Modawi, M.D. have ACO affiliation data?

Imad Salah Modawi, M.D. is shown with ACO affiliation data for McLaren High Performance Network, LLC (MSSP, ACO ID A3317), Mosaic ACO (MSSP, ACO ID A5033), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Imad Salah Modawi, M.D.?

Imad Salah Modawi, M.D. is linked to KIDNEY DISEASE & HYPERTENSION, P.C. (billing NPI 1982701256) in the available physician profile data.

Does Imad Salah Modawi, M.D. have Open Payments data?

Imad Salah Modawi, M.D. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.